607 related articles for article (PubMed ID: 26925973)
21. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract][Full Text] [Related]
22. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ
Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551
[TBL] [Abstract][Full Text] [Related]
23. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
24. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
25. Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array.
Di Marco M; Astolfi A; Grassi E; Vecchiarelli S; Macchini M; Indio V; Casadei R; Ricci C; D'Ambra M; Taffurelli G; Serra C; Ercolani G; Santini D; D'Errico A; Pinna AD; Minni F; Durante S; Martella LR; Biasco G
Mol Med Rep; 2015 Nov; 12(5):7479-84. PubMed ID: 26397140
[TBL] [Abstract][Full Text] [Related]
26. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.
Garralda E; Paz K; López-Casas PP; Jones S; Katz A; Kann LM; López-Rios F; Sarno F; Al-Shahrour F; Vasquez D; Bruckheimer E; Angiuoli SV; Calles A; Diaz LA; Velculescu VE; Valencia A; Sidransky D; Hidalgo M
Clin Cancer Res; 2014 May; 20(9):2476-84. PubMed ID: 24634382
[TBL] [Abstract][Full Text] [Related]
27. Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.
Reinhold WC; Sunshine M; Varma S; Doroshow JH; Pommier Y
Clin Cancer Res; 2015 Sep; 21(17):3841-52. PubMed ID: 26048278
[TBL] [Abstract][Full Text] [Related]
28. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
[TBL] [Abstract][Full Text] [Related]
29. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
[TBL] [Abstract][Full Text] [Related]
30. Computational analysis in cancer exome sequencing.
Evans P; Kong Y; Krauthammer M
Methods Mol Biol; 2014; 1176():219-27. PubMed ID: 25030931
[TBL] [Abstract][Full Text] [Related]
31. Genomic landscape of liposarcoma.
Kanojia D; Nagata Y; Garg M; Lee DH; Sato A; Yoshida K; Sato Y; Sanada M; Mayakonda A; Bartenhagen C; Klein HU; Doan NB; Said JW; Mohith S; Gunasekar S; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Myklebost O; Yang H; Dugas M; Meza-Zepeda LA; Silberman AW; Forscher C; Tyner JW; Ogawa S; Koeffler HP
Oncotarget; 2015 Dec; 6(40):42429-44. PubMed ID: 26643872
[TBL] [Abstract][Full Text] [Related]
32. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
Glinsky GV
Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
[TBL] [Abstract][Full Text] [Related]
33. Integrated next-generation sequencing analysis of whole exome and 409 cancer-related genes.
Shimoda Y; Nagashima T; Urakami K; Tanabe T; Saito J; Naruoka A; Serizawa M; Mochizuki T; Ohshima K; Ohnami S; Ohnami S; Kusuhara M; Yamaguchi K
Biomed Res; 2016; 37(6):367-379. PubMed ID: 28003584
[TBL] [Abstract][Full Text] [Related]
34. A mutational comparison of adult and adolescent and young adult (AYA) colon cancer.
Tricoli JV; Boardman LA; Patidar R; Sindiri S; Jang JS; Walsh WD; McGregor PM; Camalier CE; Mehaffey MG; Furman WL; Bahrami A; Williams PM; Lih CJ; Conley BA; Khan J
Cancer; 2018 Mar; 124(5):1070-1082. PubMed ID: 29194591
[TBL] [Abstract][Full Text] [Related]
35. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
36. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv J; Wang J; Chang S; Liu M; Pang X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
[TBL] [Abstract][Full Text] [Related]
37. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics.
Helsten T; Kato S; Schwaederle M; Tomson BN; Buys TP; Elkin SK; Carter JL; Kurzrock R
Mol Cancer Ther; 2016 Jul; 15(7):1682-90. PubMed ID: 27196769
[TBL] [Abstract][Full Text] [Related]
38. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS
Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422
[TBL] [Abstract][Full Text] [Related]
39. Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines.
Goecks J; El-Rayes BF; Maithel SK; Khoury HJ; Taylor J; Rossi MR
Cancer Med; 2015 Mar; 4(3):392-403. PubMed ID: 25594743
[TBL] [Abstract][Full Text] [Related]
40. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
